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Since their discovery in the late 1970s, protein kinase C (PKC) isozymes represent one of the most extensively studied signaling
kinases. PKCs signal through multiple pathways and control the expression of genes relevant for cell cycle progression,
tumorigenesis and metastatic dissemination. Despite the vast amount of information concerning the mechanisms that control PKC
activation and function in cellular models, the relevance of individual PKC isozymes in the progression of human cancer is
still a matter of controversy. Although the expression of PKC isozymes is altered in multiple cancer types, the causal relationship
between such changes and the initiation and progression of the disease remains poorly defined. Animal models developed in
the last years helped to better understand the involvement of individual PKCs in various cancer types and in the context of specific
oncogenic alterations. Unraveling the enormous complexity in the mechanisms by which PKC isozymes have an impact on
tumorigenesis and metastasis is key for reassessing their potential as pharmacological targets for cancer treatment.
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INTRODUCTION
Protein kinase C (PKC), a prototypical class of serine/threonine
kinases, exemplifies specific signaling molecules that link multiple
cellular processes to cancer. Originally identified as a cellular
receptor for the phorbol ester tumor promoters more than 30
years ago,1–2 PKC became the subject of intense studies by
academic laboratories and pharmaceutical companies (450 000
citations in PubMed, which is even more than other ABC kinases
such as PKA or PKB/Akt). Extensive work established these kinases
as pleiotropic regulators of cell function, including proliferation,
differentiation, survival and motility.3 To date, it is clear that PKCs
are associated with a number of diseases, including cancer,
cardiovascular dysfunctions and metabolic disorders. The
complexity in PKC signaling arises from the fact that PKC is a
multifamily of structurally related kinases with diverse biological
functions. Indeed, mammalian PKCs encompass 10 members that
represent the products of nine different genes located in different
chromosomes. PKC isozymes have been classified into three
groups: ‘conventional’ or ‘classical’ PKCs (cPKCs) that are
composed of PKCa, two splice variants of PKCb (PKCbI and
PKCbII) and PKCg; ‘novel’ PKCs (nPKCs), a group that includes
PKCd, PKCe, PKCZ and PKCy; and ‘atypical’ PKCs (aPKCs) z and
i (l). cPKCs and nPKCs are activated by diacylglycerol (DAG), a
lipid second messenger transiently generated upon stimulation of
membrane receptors such as tyrosine-kinase and G-protein-
coupled receptors. DAG mimics the action of phorbol esters, as
they bind to the C1 domains in the regulatory region. Only the
cPKCs are calcium-sensitive, as they have a calcium-binding C2
domain (the C2 domain in nPKCs is calcium-insensitive). aPKCs
display unique regulatory properties: they are unable to bind DAG
or calcium and rather depend on protein–protein interactions and
phosphorylation for their activation3 (Figure 1).
In the last years we have witnessed major advances in our
understanding of the roles of PKCs in tumor development and
progression, including in late stages of the disease and metastasis.
This review summarizes the knowledge on PKC isozymes in cancer
progression and highlights the most recent advances in the field,
particularly using genetically modified mouse models in the
context of specific oncogenic alterations.
PKC ISOZYME EXPRESSION IN CANCER: CHANCE OR
CAUSALITY?
Expression levels of PKC isozymes change in neoplastic diseases.
The overall picture is, however, confusing, partly due to potential
issues of antibody specificity in immunohistochemical studies and
lack of appropriate validation controls in many reports. The
standing question is whether those changes in expression have
any causal relationship with disease progression. An additional
complication is that, in an era when microarray mRNA databases
are routinely used, there are significant discrepancies between the
available information on PKC expression at the mRNA and protein
levels. This can be epitomized for PKCe, an isozyme that is
markedly upregulated in most epithelial cancers at the protein
level,4–7 but shows only marginal or no changes in mRNA
databases (Figure 2). Whereas high expression of PKCe in tumors
may involve changes at a transcriptional level, expression under-
estimation by databases may relate to post-translational events
that ultimately modify protein stability. Modeling expression
patterns from mRNA expression databases, which in most cases
have not been generated from microdissected tissues, can distort
the actual profile of PKC protein expression in tumors and
ultimately mislead our efforts to correlate those changes with
clinicopathological outcomes.
Another important issue that received little attention is the
activation status of PKC isozymes in cancer. There is little
experimental evidence supporting either hyperactivation or
hypoactivation of PKCs in human tumors. Unlike other important
kinases implicated in cancer progression, such as Erk, JNK or Akt,
phosphorylation of PKCs does not necessarily correlate with
activation status. One impediment to address this important
matter is the lack of reliable readouts associated with the
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activated status of individual PKCs, in particular PKC isozyme-
specific substrates that could be detected in human tumors.
Genetically encoded reporters for PKC isozymes reliably detect
enzyme activation and substrate phosphorylation in cellular
models in culture;8–12 however, we still lack tools to detect
activated PKCs or their specific substrates in tumors by
immunohistochemistry. The association of PKCs to membranes
is a requisite for the activation of DAG/phorbol ester-regulated
PKCs.3 Whereas some exceptions have been reported, such as the
activation by proteolytic cleavage,13 cPKCs and nPKCs translocate
to the plasma membrane in response to stimuli such as growth
factor receptor activation. Although less understood at a
mechanistic level, cPKCs and nPKCs can also redistribute to a
number of intracellular compartments, including the translocation
to the mitochondria, Golgi, endoplasmic reticulum and nuclear
membrane. Constitutive association of PKCs to internal
membranes has also been reported.14–17 At present, we do not
understand well the significance of such compartmentalization
and whether PKCs are fully activated in discrete intracellular
locations due to differential membrane compositions, DAG
availability, and/or the presence of isozyme-specific protein
partners that cooperate for the transition to an activated status.
All these factors conspire against a full appreciation on how PKC
activation contributes to disease progression.
PKCa: TUMOR PROMOTER OR TUMOR SUPPRESSOR?
PKCa has been long recognized as a regulator of multiple aspects of
tumor growth, including proliferation, survival, differentiation and
motility. As several studies linked PKCa to enhanced proliferation
and anti-apoptotic signals,18–22 there has been significant interest in
this kinase as a potential target for cancer therapy. However, PKCa
had limited success as a drug target for cancer. Indeed, due to its
very complex and highly tissue-specific functions, PKCa acts as a
tumor promoter or a tumor suppressor depending on the context.
To add another level of complexity, PKCa is upregulated in some
Figure 1. Structure of PKC isozymes. PKCs are multidomain proteins that are regulated by lipids and protein–protein interactions. DAG
generated upon activation of receptors causes the activation of cPKCs and nPKCs, and its actions are mimicked by phorbol esters. aPKCs do
not respond to DAG or phorbol esters. PKCs activate a number of signal transduction pathways that regulate tumorigenesis and metastasis.
Figure 2. Expression of PKCe in prostate cancer. (a) In silico PKCe mRNA expression profiling in 81 normal/normal adjacent prostate tumors, 48
primary prostate carcinomas and 25 prostate cancer metastasis obtained from a publicly available data set (GSE6919). PRKCE, PKCe gene.
(b) Meta-analysis of PRKCE mRNA expression across 16 prostate microarray studies from the Oncomine database. This meta-analysis shows
non-statistically significant differences in PRKCE mRNA expression (combined P-value¼ 0.41) between normal and prostate cancer groups.
Red intensity is a representative of the statistical significance in mean difference between normal and prostate cancer for each study.
(c) Expression of PKCe in ‘normal’ immortalized prostate epithelial RWPE-1 cells versus prostate cancer cells. This figure was originally
published by Garg et al.,176 The American Society for Biochemistry and Molecular Biology.
PKC isozymes and cancer
R Garg et al
5226
Oncogene (2014) 5225 – 5237 & 2014 Macmillan Publishers Limited
cancers (such as bladder, endometrial and breast cancer) and
downregulated in others (such as colorectal tumors and malignant
renal cell carcinomas23,24). There is little information on substrates
specifically phosphorylated by PKCa or genetic programs controlled
by PKCa, thus rendering our comprehension of the molecular basis
of this functional diversity incomplete.
Early studies in glioma cellular models established that PKCa is
upregulated relative to astrocytes. Antisense oligonucleotides
against PKCa inhibit the proliferation of glioma cells.25 Consistent
with these results, overexpression of PKCa in U87 glioblastoma
cells enhances proliferation. Although overexpression of PKCa did
not protect U87 cells from apoptosis by etoposide, other studies
documented that PKCa renders enhanced resistance to apoptosis
in response to radiation and chemotherapy.18,26,27 In U1242
glioblastoma cells, PKCa regulates the activation of nuclear factor
kappa B (NF-kB), which results in a pro-survival phenotype.28
Aprinocarsen (Ly900003, ISIS 3521), an antisense oligonucleotide
directed against the 30-untranslated region of PKCa, arrests A172
glioma cells and induces p53. Aprinocarsen also impairs tumor
growth in xenograft models. In combination with other
chemotherapeutic agents, aprinocarsen was shown to have
additive or super-additive antitumor effects.29–31 Despite
encouraging responses in early clinical trials, this anti-PKCa agent
failed to make it into phase III clinical trials either alone or in
combination with other agents.29 Another PKCa inhibitor, the
staurosporine analogue UCN-0132 proved to be a potent antitumor
agent in preclinical models, but its effect cannot be explained
simply by PKCa inhibition.33 It is also intriguing that PKCa RNA
interference depletion but not PKCa inhibition impairs the growth
of glioma cell lines, suggesting that the effect is independent of
the catalytic phosphotransferase activity of the enzyme.18
Another interesting link between PKCa and cancer progression
has been established in breast. Ways et al.34 showed that ectopic
overexpression of PKCa in MCF-7 breast cancer cells (which
express low levels of PKCa) enhances proliferative rate, confers
anchorage-independent growth and tumorigenic potential in
nude mice, and drastically alters cell shape by inducing loss of
an epithelioid morphology. PKCa overexpressing MCF-7 cells have
reduced estrogen receptor (ER) levels, suggesting that PKCa
contributes to the switch from ER-positive to ER-negative status.
Likewise, Tonetti et al.35 found that stable overexpression of PKCa
in T47-D breast cancer cells is accompanied by downregulation of
ER function and confers hormone-independent tumor growth that
cannot be inhibited by tamoxifen.36 A recent study suggests that
this effect may be mediated by Notch-4.37 Elevated PKCa
expression was suggested to be a predictor of tamoxifen
treatment failure, which fits with the observation that patient
tumor samples with elevated PKCa levels are generally negative
for ER expression, and these patients respond less to endocrine
therapy.38,39 A recent study by Larsson and coworkers40
demonstrated that PKCa levels correlates with ER and
progesterone receptor negativity, proliferative activity and tumor
grade. Thus, altogether it seems that PKCa is a biomarker for poor
prognosis and endocrine therapy resistance in breast cancer. PKCa
is also an effector of ErbB2 in breast cancer cells, and ErbB2 small
interfering RNA depletion decreases PKCa protein levels.
Moreover, ErbB2 overexpression correlates with membrane-
associated staining of PKCa in human breast cancer specimens,
suggesting that ErbB2 drives the constitutive activation of PKCa.41
Go6976, a pharmacological inhibitor of cPKCs,42 abrogates ErbB2-
mediated upregulation of urokinase-type plasminogen activator
and cell invasion.43 Whereas PKCa expression is higher in triple-
negative breast cancers than in other subtypes,44 we still need to
underscore meaningful associations of this PKC with genetic
alterations specific for each breast cancer subtype.
In a very recent study by the Weinberg laboratory, PKCa was
found to be enriched in epithelial-to-mesenchymal-induced
mammary cells.45 Interestingly, inhibitors targeting PKCa
preferentially kill mesenchymal cells relative to epithelial cell
lines, and likewise, depletion of PKCa using small hairpin RNA
results in a substantial loss of mesenchymal cells. A PKCa signaling
network is activated preferentially in cancer stem cells by platelet-
derived growth factor and involves the transcription factor FRA1
(Fos-related antigen 1). The activation of the PDGFR-PKCa-FRA1
pathway in breast cancer stem cells makes them particularly
susceptible to pharmacological inhibition of PKCa. Whereas the
relevance of this pathway has to be established in other cancer
types, this study certainly shed light into the potential therapeutic
value of targeting PKCa in epithelial cancers.
Despite the reported pro-tumorigenic effects of PKCa, it has
been also described as a growth inhibitory kinase in several cell
types. For example, activation of PKCa in non-small cell lung
cancer (NSCLC) cells leads to p21Cip1 upregulation, inhibition of
cell growth and senescence.46 Not surprisingly, aprinocarsen
showed no significant benefit for NSCLC patients, either alone or
in combination with other chemotherapeutic agents.29
Years ago, Black and coworkers47,48 reported that PKCa
activation triggers a program of cell cycle exit-specific events in
intestinal crypts through the repression of cyclin D1 translation.
This effect implicates the activation of the translational repressor
4E-BP1 through a phosphatase 2A-dependent mechanism and in a
PI3K/Akt-independent manner.49 PKCa also inhibits the Wnt/b-
catenin pathway in colon cancer cells and represses the expression
of b-catenin target genes such as c-Myc,50 a mechanism that may
involve receptor-related orphan receptor alpha RORa.51
Interestingly, a small-molecule screening identified a compound
(CGK062) that promotes PKCa-mediated phosphorylation of b-
catenin, leading to its proteasomal degradation. This compound
has antitumor effects in nude mice.52 The expression of PKCa in
proliferating intestinal epithelial cells is repressed both in vitro and
in vivo by the SOX9 transcription factor.53 All neoplasm arising in
APC /þ mice, which develop multiple intestinal neoplasia, express
low levels of PKCa. Remarkably, loss of PKCa directly correlates
with aggressiveness of intestinal tumors. Furthermore, tumor
formation and aggressiveness are enhanced in double transgenic
APCMin/þ ; PKCa / mice (Figure 3a). Interestingly, spontaneous
intestinal tumors develop in PKCa / mice.54,55 PKCa also
suppresses skin tumor formation induced by DMBA (7,12-
dimethylbenz[a]anthracene). However, PKCa deficiency does not
alter the size or malignancy of skin tumors.56
PKCa activation by phorbol esters contributes to cell death in
androgen-dependent prostate cancer cells. Activation of PKCa in
Figure 3. Loss of PKCa gene enhances tumor progression.
(a) Deletion of the PKCa gene enhances the formation of tumors
in APCMin/þ mice, and those tumors show a more aggressive
phenotype. (b) Deletion of PKCa in K-Ras mutant mice resulted in
progression of benign tumors to adenocarcinoma. Tumors exhibit
high frequency and grade, and are bigger in size.
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LNCaP cells leads to a rapid and reversible dephosphorylation of
Akt possibly via activation of a protein phosphatase 2A
phosphatase.57 Stable DAG analogues with preferred selectivity
for PKCa also induce apoptosis in LNCaP cells.58 A kinase-dead
PKCa mutant blocks the apoptotic response elicited by a
combination of phorbol 12-myristate 13-acetate (PMA) treatment
and radiation, and a constitutively active PKCa mutant sensitizes
cells to radiation treatment. Although radiation alone reduces
initial LNCaP tumor growth and serum prostate-specific antigen
levels in mice, combinatorial treatment with PMA or a specific
PKCa DAG activator eliminates tumor growth and drastically
reduces prostate-specific antigen levels.59
A very interesting recent study by the group of Alan Fields
reported that PKCa has a key role in K-Ras-mediated lung
tumorigenesis.60 There is an evident loss of expression of PKCa
in primary human NSCLC tumors. Remarkably, PKCa-knockout
mice display enhanced K-Ras lung tumorigenesis (Figure 3b) and
bypass oncogene-induced senescence. The tumor promoting
effect caused by loss of PKCa may involve the expansion of
bronchoalveolar stem cells. Mechanistic analysis determined that
loss of PKCa reduces the activation of p38 mitogen-activated
protein kinase in bronchoalveolar stem cells from K-Ras tumors
and augments transforming growth factor b1 (TGFb1) mRNA
levels. Moreover, a TGFb receptor inhibitor reversed the effect of
PKCa loss in K-Ras/PKCa-depleted tumors. This study reported the
inhibitors of DNA binding (Id) Id1-3 as potential downstream
targets of PKCa-dependent tumor suppressor activity, as also
observed in other intestinal cells and fibroblasts.61,62 Therefore,
PKCa suppresses tumor initiation and progression in the K-Ras
lung cancer mouse model through a p38 mitogen-activated
protein kinase/TGFb signaling axis.
PKCa has been implicated in invasion and metastasis, mostly as
a positive regulator.63–68 In breast cancer cells, ErbB2-dependent
activation of PKCa promotes cell invasion.41 PKCa overexpressing
MCF-7 breast cancer cells display enhanced motility, which
was attributed to decreased expression of E-cadherin and
b-catenin and high expression of matrix metalloprotease
(MMP)-2/MMP-9.69,70 A specific PKCa peptide inhibitor
significantly reduced metastasis of mouse mammary cancer cells
to the lungs. Analysis of highly metastatic (4T1) and non-
metastatic (JC) mouse mammary cells indicates that the basal
activation of PKCa is higher in the former. Treatment with this
PKCa antagonistic peptide did not affect tumor growth but
blocked metastasis of 4T1 cells to the lungs. PKCa inhibition blocks
metastasis by inhibiting the activation of MMPs in combination
with decreased NF-kB activity and CXCL12 receptor levels.71
PKCb ISOZYMES: SPLICED VARIANTS WITH DISTINCT
INVOLVEMENT IN CANCER
PKCbI and PKCbII, spliced variants encoded by the PRKCB gene
have differential tissue expression and a distinct involvement in
cancer. PKCb isoforms have been implicated in the progression of
many cancer types, including lymphoma, glioblastoma, breast,
prostate and colorectal cancers.72–76 It is not fully understood why
PKCb isoforms have in some cases different functions. This may
relate to unique lipid- and protein interactions via their different
C-terminal domains that confer distinctive localization
properties.77–79 However, many studies using pharmacological
agents do not distinguish between PKCb subtypes.
Early studies reported elevated PKCbII levels both during the
initial stages of tumorigenesis and in colonic carcinomas relative
to normal colonic tissue.80–82 Spindler et al.83 reported that 18% of
primary adenocarcinomas exhibit very high levels of PKCbII,
which correlates with poor survival rates. PKCbII has been
implicated in colon cancer cell proliferation in vitro.84,85 Murray
et al.86 generated a transgenic mouse model overexpressing
PKCbII in the intestinal epithelium. In addition to epithelial
hyperproliferation, these mice display increased susceptibility to
carcinogen-induced preneoplastic lesions in the colon. The
phenotype has been linked to repression of TGFb signaling and
elevated COX-2 expression.72 In the proximal colon, activated
K-Ras induces the expression of PKCbII, activation of the Mek/Erk
signaling axis and increased epithelial cell proliferation.87 In a
cellular model of intestinal cells, stable overexpression of PKCbII
confers an invasive phenotype mediated by a Ras/Mek/PKCi/Rac1-
dependent pathway.88 The role of PKCbI in the colon is less clear.
Overexpression of PKCbI suppresses the growth of HT29 and
SW480 colon cancer cell xenograft.89 However, other report shows
that expression of PKCbI confers resistance to apoptosis by tumor
necrosis factor a (TNFa) and paclitaxel.90
PKCbI expression positively correlates with high Gleason scores
in prostate carcinomas, and inhibition of this kinase blocks
androgen receptor-induced tumor cell proliferation in vitro and
xenograft growth in vivo. Notably, PKCbI phosphorylates histone
H3 and inhibits androgen-dependent transcription.91 A study
using a specific PKCbII peptide inhibitor showed that this isoform
is involved in prostate cancer cell proliferation. PKCbII also has an
important role in endothelial cell proliferation, and inhibition of
PKCbII reduces angiogenesis. These effects were linked to
dysregulation of cytokinesis and microtubule organization.73
Enzastaurin, an inhibitor with some degree of specificity toward
PKCb, displays antiproliferative effects in PC-3 cells.92
Overexpression of either PKCbI or PKCbII in MCF-7 breast cancer
cells promotes cell growth and enhances cyclin D1 levels, whereas
dominant-negative PKCb mutants inhibit growth.93 On the
other hand, another report showed that PKCbI overexpression
induces a less aggressive biological behavior in MCF-7 cells
characterized by reduced tumor formation.94 In a murine
mammary model, PKCbI inhibits tumorigenesis despite having a
positive effect on growth in culture. Moreover, tumor cells that
overexpress PKCbI have attenuated metastatic capacity to the
lungs.95 Enzastaurin has significant effects on the growth of breast
cancer cells in vitro and in vivo.96,97 High levels of PKCbII have
been reported in several breast cancer cell lines and patient
samples. The levels of cytoplasmic PKCbII expression positively
correlate with ErbB2/Her2 levels, whereas nuclear PKCbII positively
correlates with ER levels.98
PKCbII is expressed in human NSCLC specimens with significant
variability, both in tumor cells and the stroma.99 Enzastaurin in
combination with the antifolate pemetrexed causes G2/M
checkpoint abrogation and apoptosis in lung cancer cells.100 In
cell culture, enzastaurin is a potent inhibitor of vascular endothelial
growth factor-stimulated proliferation of endothelial cells, and
in vivo this inhibitor causes a significant reduction in intratumoral
vessels that parallels a delay in lung cancer tumor growth.99
Enzastaurin also enhances the anti-angiogenic effects of radiation
in NSCLC models.101 The PKCb inhibitor, Enzastaurin, regulates
proliferation of glioblastoma cells by supporting the activity of
GSK3, S6 kinase and Akt.102 The effect of the PKCb inhibitor was
also shown in U87MG human glioblastoma cells inoculated into
nude mice. Enzastaurin proved to be efficient as an anti-
angiogenic compound in models of glioblastoma,76 however
clinical trials in patients with recurrent high-grade glioma show
limited success when this inhibitor was used as a monotherapy.103
Patients with diffuse large B-cell lymphoma that express PKCb
have reduced overall survival compared with those that are
negative for this kinase.104,105 Enzastaurin displays pro-apoptotic
properties in T-cell and B-cell lymphoma cell lines.106,107 There is
significant interest in using this PKCb inhibitor for the treatment of
various types of lymphomas, both as a single agent and in
combination therapies.108,109 Taking advantage of a PKCb-
knockout mouse model, it has been recently demonstrated that
stromal PKCbII is indispensable for the survival of chronic
lymphocytic leukemia B cells. The fact that stromal PKCbII is
upregulated in biopsies from patients with chronic lymphocytic
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leukemia , and that chronic lymphocytic leukemia cells induce the
expression of stromal PKCb,110 highlights the need to better
understand how this PKC contributes to cancer development in
the context of the different tumor microenvironments.
PKCd: COMPLEX ROLES IN APOPTOSIS, TUMOR GROWTH AND
METASTASIS
PKCd has been widely characterized as a pro-apoptotic and
antiproliferative kinase. In addition, PKCd has been broadly
implicated as a death mediator of chemotherapeutic agents and
radiotherapy.111–114 PKCd is involved both in DNA damage and
receptor-mediated cell death.3,114,115 Initial work from the Reyland
lab showed that PKCd is cleaved by caspase-3 and mobilizes from
the cytoplasm to the nucleus after treatment with genotoxic
agents.13 Other studies showed that PKCd-mediated apoptosis
involves the allosteric activation of the enzyme rather than
proteolytic cleavage. For example, in androgen-dependent
prostate cancer cells, PKCd activation triggers an apoptotic
response without the generation of a constitutively active
catalytic fragment.116 This effect involves the activation of the
p38 mitogen-activated protein kinase cascade57 and is mediated
by a RhoA/ROCK/p21Cip1-dependent pathway.117 PKCd-mediated
apoptosis in androgen-dependent prostate cancer cells occurs
through the autocrine secretion of TNFa and TNF-related
apoptosis-inducing ligand, which induce caspase-8 cleavage
through the JNK and p38 mitogen-activated protein kinase
cascades.118–120 The discrepancies in the mechanisms of PKCd
activation among the various studies may be explained by cell
type differences and nature of the stimulus.
An inhibitory role for PKCd in proliferation has been reported in
a number of cellular models. The initial observations by Mischak
et al.121 that ectopic overexpression of PKCd confers growth
inhibitory properties to NIH 3T3 cells, were later recapitulated in
many other cell lines. Depending on the cell type, activation of
PKCd can induce cell cycle arrest either in G1 or G2.48,122 Our
laboratory showed that treatment of lung cancer cells with
phorbol esters induces cell cycle arrest in G1 through the
induction of p21cip1 and Rb dephosphorylation.123 However, it
has been also noted that ectopic expression of PKCd stimulates
quiescent cells to initiate the G1 phase cell cycle progression.
Notably, PKCd-overexpressing cells arrest in S-phase rather than
completing the cell cycle.124
It is important to mention that studies ascribed pro-survival
properties to PKCd in a number of tumor models, including breast,
lung, pancreatic and liver cancer.115 Moreover, ectopic expression
of PKCd in mammary cells confers anchorage-independent growth
properties and enhances the resistance to apoptotic stimuli.125 The
scenario that PKCd could be a tumor promoting kinase rather than
a tumor suppressor began to shape new paradigms in PKC isozyme
function, and clearly points to an exquisite cell type selectivity.
Data from patients cannot point to a clear link between PKCd
expression levels and clinical outcome. Loss of PKCd expression
has been reported in a few cancer types,126–128 but this
downregulation could not be unambiguously linked to
tumorigenesis. PKCd is upregulated in some cancer types.129,130
PKCd is barely detected in normal prostate epithelial cells;
however, high PKCd expression could be observed in prostate
preneoplastic lesions and carcinomas.131,132 In breast cancer
specimens, PKCd mRNA levels are significantly higher in ER-
positive tumors and a positive correlation between high PKCd
mRNA levels and reduced overall survival has been reported.133
Interestingly, the expression of PKCy, an isozyme related to PKCd,
is dysregulated in some cancers.130,134–136
Emerging studies using genetically engineered mice began to
shed light into the involvement of PKCd in tumorigenesis. PKCd
skin transgenic mice are resistant to tumor promotion by DMBA/
PMA.137 Studies using PKCd-knockout mice revealed contrasting
effects particularly in the context of specific genetic alterations.
Reyland and coworkers138 investigated the involvement of PKCd
in K-Ras-dependent tumorigenesis and found that the incidence
of urethane-induced lung tumors (which display activating
mutations in K-Ras) is reduced in a PKCd-null background.
Moreover, PKCd RNA interference depletion inhibits anchorage-
independent growth, invasion, migration and tumorigenesis in
K-Ras-dependent NSCLC cells. The Reyland lab also described a
positive role for PKCd in mammary tumorigenesis in the context of
ErbB2 overexpression. A meta-analysis of ErbB2-positive breast
cancers shows increased PKCd expression and a negative
correlation between PKCd expression and prognosis. Most
remarkably, there is a significant delay in tumor onset in MMTV-
ErbB2(Neu) in a PKCd-null background.139 A tumorigenic role for
PKCd has been also reported in a model of pancreatic cancer.
Indeed, overexpression of PKCd (as observed in human ductal
carcinomas) leads to increased anchorage-independent growth
and tumorigenesis in vivo.140 In addition, in a PC-3 xenograft
model, PKCd activation promotes tumor growth and increases
angiogenesis through a mechanism that involves reactive oxygen
species, nicotinamide adenine dinucleotide phosphate and
hypoxia-inducible factor 1a.141
PKCd generally has a positive role in migration and invasive-
ness.142–145 In prostate cancer cellular models, PKCd has been
implicated in invasiveness and the control of collagen secretion
induced by overexpression of the oncoprotein PCPH.132 Breast
cancer models provided controversial evidence for the
involvement of PKCd in invasion. Whereas a study showed that
PKCd overexpression in highly motile BT-549 breast cancer cells
reduces migration and PKCd downregulation enhances motility
and MMP-9 secretion in MCF-7 cells146 other study reported that
enhanced migration induced by forced epidermal growth factor
receptor overexpression in MCF-7 cells requires PKCd.147 PKCd was
found to inhibit the production of proteolytic enzymes in murine
mammary cells, possibly limiting metastatic dissemination.125
Downregulation of PKCd suppresses lung colonization in the
murine mammary breast cancer model MTLn3 without affecting
the growth of primary tumor.148 Studies performed in BL6 murine
melanoma cells showed that PKCd overexpression increases their
metastatic capacity in vivo, possibly due to an increase in the
plasma levels of TGF-b1.149,150 A similar pro-metastatic effect of
PKCd has been shown in the human pancreatic cell line PANC1.140
The multiplicity of effects regulated by PKCd and the complexity
of the effects in cell cycle regulation, cell motility, tumorigenicity
and metastasis, both in positive and negative manners (Figure 4),
would argue that this kinase is not a likely candidate for the
therapy of cancer.
PKCe: AN ONCOGENIC AND METASTATIC KINASE
PKCe has been originally described as an oncogenic
kinase121,151,152 and is known to signal via the Ras-Raf-1
signaling pathway153–156 as well as other pathways. PKCe-
transformed fibroblasts secrete increased amounts of TGF-b and
possibly other mitogens, an indication that growth autocrine
loops may account for its oncogenic activity157,158 PKCe is
overexpressed in a large number of cancers. For example, PKCe
is overexpressed inB75% of primary tumors from invasive ductal
breast cancer patients. Increased PKCe staining correlates with
high histological grade, positive ErbB2/Her2 status and negative
estrogen and progesterone receptor status.7 Overexpression of
PKCe has been reported in the majority (490%) of primary NSCLC
cancers relative to normal lung epithelium.5 PKCe levels are
elevated in prostate cancer relative to benign prostatic
epithelia,159 and a correlation with aggressiveness of human
prostate cancer has been found.4 PKCZ, an isoform related to
PKCe, has also been shown to be upregulated in some
cancers,160,161 but downregulated in others.162
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Not surprisingly, studies from several laboratories highlight a
role for PKCe in cell cycle control, specifically in G1 to S
progression.163–165 In addition, PKCe promotes survival in many
cell types.6,166–168 The survival activity of PKCe involves the
modulation of caspases and Bcl-2 family members.166,169–171
Forced expression of PKCe in LNCaP prostate cancer cells
confers resistance to PMA-induce apoptosis by preventing Bax
oligomerization; moreover, it leads to accelerated proliferation of
LNCaP cells due to constitutive activation of the Erk cascade.167
Our laboratory recently demonstrated that PKCe modulates Bad
phosphorylation at Ser112 to protect LNCaP prostate cancer cells
against apoptosis induced by PMA or TNFa.170 PKCe protects
glioma and lung cancer cells from TNF-related apoptosis-inducing
ligand-induced apoptosis.168,172,173 Subsequent studies by Basu
and coworkers174 revealed that PKCe inhibits cell death in breast
cancer cells, partly by preventing the activation and translocation
of Bax to the mitochondria. PKCe inhibition/depletion impairs
proliferation and anchorage-independent growth of human
NSCLC cells.5,175 Many pro-apoptotic genes upregulated upon
PKCe RNA interference depletion in lung cancer cells are also
downregulated in human lung adenocarcinomas.175 RWPE-1 cells,
a model of normal immortalized prostate epithelial cells, express
very low levels of PKCe as compared with different human
prostate cancer lines, and ectopic expression of PKCe in RWPE-1
cells confers growth advantage and leads to Erk and Akt
activation.6 Recently, our laboratory identified a key role for
PKCe as a mediator of NF-kB signaling in prostate cancer.176 PKCe
inhibition/depletion impairs constitutive and TNFa-dependent
activation of NF-kB as well as the induction of NF-kB responsive
genes pertaining to cell survival, proliferation, metastasis and
invasion, such as COX-2, MMP-9, vascular endothelial growth
factor and interleukin-6.176
Overexpression of PKCe in androgen-dependent LNCaP cells
initiates tumor growth in vivo both in intact and castrated athymic
nude mice,177 thereby indicating that PKCe has the potential to
advance the progression of prostate cancer and initiate recurrent
tumor growth in the absence of androgens. In concordance,
another study found that PKCe overexpression in breast cancer
cells causes tumor growth in BALB/c mice with significant increase
in the incidence and number of spontaneous experimental lung
metastases.95 In line with these results, depletion of PKCe from
lung cancer cells using small hairpin RNA markedly inhibited
xenograft growth in nude mice. Furthermore, the PKCe
translocation inhibitor peptide eV1-2 blocks NSCLC tumor
growth in nude mice. Moreover, both small hairpin RNA
depletion and pharmacological inhibition of PKCe causes a
strong induction of cell death in xenograft tumors.175
Unfortunately, there has been little work intending to
recapitulate PKCe overexpression as observed in human cancer.
Our laboratory developed prostate-specific transgenic mice that
overexpress PKCe in the normal prostate in vivo under the control
of the androgen-responsive probasin (PB) promoter, which leads
to the formation of preneoplastic lesions (Figure 5). Conversely,
similar mouse models for other PKCs (PB-PKCa and PB-PKCd mice)
do not display any noticeable phenotypic changes in the prostate.
Furthermore, elevated phospho-Akt as well as hyperactivation of
Akt effectors S6 and mTOR could be detected in hyperplasia and
prostatic intraepithelial neoplastic (PIN) lesions from PB-PKCe
transgenic mice. Besides, PKCe overexpression confers resistance
to apoptosis induced by androgen ablation, highlighting a pro-
survival role of PKCe in the mouse prostate.6 Hyperactivation of
NF-kB and Stat3 were evident in the PIN lesions of PB-PKCe
transgenic mice relative to the normal areas or regions with mild
hyperplasia.6,176
Prostates of TRAMP mice (a model that spontaneously develops
progressive invasive prostate cancer) have very high PKCe protein
levels compared with prostates of control mice.4 A recent study
demonstrated that genetic ablation of PKCe in TRAMP mice
inhibits prostate cancer development and metastasis.178 Deletion
of PKCe in TRAMP mice decreases the phosphorylation/activation
of Stat3 as well as its nuclear translocation and DNA-binding
activity. It has been proposed that loss of PKCe in TRAMP
transgenic mice reduces the expression of proliferation, survival
and metastasis markers, including COX-2, Bcl-xL, cyclin D1 and
vascular endothelial growth factor as well as it decreases serum
interleukin-6 levels.
A growing body of evidence indicates that PKCe is implicated in
tumor cell invasion and metastasis. Enhanced PKCe levels are
associated with invasion and/or metastasis of human breast,
glioma and renal cell carcinoma.7,164,179 PKCe contains an actin-
binding motif that positions this kinase within a cytoskeletal
matrix where many PKC substrates are localized.180–183 Deletion of
this motif abrogates invasion and metastatic spread of tumors
driven by PKCe overexpression.184 In human glioma cells, the PKC-
interacting protein RACK1 appears to link activated PKCe to the
integrin b chain at focal adhesions, and PKCe mediates the
adhesion and motility of cells via Erk phosphorylation.185 PKCe
also promotes the assembly of matrix adhesions containing actin
filaments and b1-integrins, and integrin signaling links PKCe to the
Akt survival pathway in recurrent prostate cancer cells.186 In
models of breast and head and neck cancer, PKCe regulates
motility and invasion, at least in part due to the activation of small
Rho GTPases, specifically RhoA and/or RhoC.7,187 Very recent work
from our laboratory showed that targeted disruption of PKCe in
lung cancer cells reduces motility through Rac1 inactivation.
Several extracellular matrix proteases are downregulated in PKCe-
depleted lung cancer cells.188 Consistent with a role for PKCe in
metastatic dissemination, PKCe-depleted NSCLC cells fail to
colonize lungs after tail vein injection in mice.188 Likewise, a
study from the Urtreger’s laboratory showed that inoculation of
Figure 4. Multiple biological functions regulated by PKCd. Studies in
cellular models established important roles for PKCd in apoptosis
and as a negative regulator of cell cycle progression. PKCd has been
also implicated in cancer cell motility and invasiveness. Studies
using animal models showed that PKCd can either act as a tumor
suppressor or contribute to tumorigenesis depending on the
context.
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PKCe overexpressing breast cancer cells in mice enhances the
incidence and number of spontaneous and experimental lung
metastases.95
Verma and coworkers189,190 generated skin transgenic mice
expressing PKCe under the control of the human K14 promoter,
which exhibit phenotypic abnormalities including inflammation,
hyperkeratosis, hyperplasia, cellular hypertrophy and ulceration.
Highly malignant and metastatic squamous cell carcinomas
develop in the skin of PKCe transgenic mice. Additionally, PKCe
overexpression has been shown to sensitize the mouse skin to
UVR-induced carcinogenesis.191 A subsequent study
demonstrated that skin transgenic PKCe mice develop a
myeloproliferative-like disease.192
Altogether, these observations establish that PKCe overexpres-
sion is linked to an aggressive phenotype and suggest that
targeting PKCe could be an effective anticancer strategy. Whereas
the development of PKCe inhibitors targeting the ATP-binding site
may be challenging due to the high homology of this site among
PKCs, agents directed against domains implicated in translocation
may be valuable. In that regard, the PKCe translocation inhibitor
eV1-2 has anti-tumorigenic activity in NSCLC cells175 and a
bifunctional peptide in which eV1-2 has been linked to the
12-mer cancer homing peptide HN1 impairs the growth of head
and neck squamous cell carcinoma cells in xenografts.193 Lastly,
Ras-driven and epithelial-to-mesenchymal-dependent phenotypes
in breast cancer cells could be reversed by PF-526355, an ATP
mimetic inhibitor with selectivity for PKCe and PKCy. This inhibitor
impairs the growth of MDA-MB-231 breast cancer xenografts in
mice, thus representing a promising agent for cancer therapy.194
ATYPICAL PKCS f AND i: OPPOSITE ROLES IN CANCER
aPKC isozymes, which comprise PKCz and PKCi (PKCl), are
structurally and functionally distinct from other PKCs in that they
have a single DAG/phorbol ester unresponsive C1 domain and
lack a C2 domain.195,196 Regardless of controversies in the
literature largely due to the use of non-specific approaches such
as inhibitory peptides and dominant-negative mutants, many
studies point to a tumor suppressor function of PKCz, whereas
PKCi essentially fulfills the criteria of an oncogenic kinase
(Figure 6).
Both up and downregulation of PKCz has been shown in human
cancer. PKCz upregulation has been reported in prostate cancer,
bladder cancer and lymphomas,197–202 whereas downregulated
expression of PKCz has been shown in glioblastoma, lung cancer,
kidney, renal clear cell carcinoma, melanoma and pancreatic
cancer.203–212 A pro-apoptotic function for PKCz has been
described in several cancer models. For example, PKCz inhibits
growth and promotes differentiation and apoptosis in colon
cancer cells. The inhibitory effect of PKCz on the transformed
phenotype of these cells suggests that downregulation of PKCz
may contribute to colon tumorigenesis.213 PKCz also exhibits a
pro-apoptotic function in ovarian cancer.214 In murine TRAMP
prostate cancer cells, expression of a constitutively activated PKCz
mutant enhances proliferation, whereas PKCz inhibition leads to
Akt activation and enhanced cell survival.215 There are several
reports, however, highlighting a pro-survival role for PKCz.216–220
PKCz-deficient mice display increased Ras-induced lung carci-
nogenesis, arguing for a role for this aPKC as a tumor suppressor
in vivo. It has been postulated that the tumor suppressor activity of
PKCz occurs through its ability to downregulate Ras-induced
interleukin-6 production. The enhanced secretion of interleukin-6
in PKCz-deficient Ras-transformed cells is essential for growth
under conditions of limited nutrients and mitogens.209 Genetic
inactivation of PKCz in mice in a Pten-deficient background leads
to invasive prostate carcinoma. A significant correlation between
PKCz and Pten levels exists in human prostate tumors, and PKCz is
significantly reduced in metastatic versus primary tumors with low
Pten. Analysis of gene signatures in PKCz-deficient cells revealed a
link with c-Myc. Indeed, c-Myc is a contributor to the more
aggressive phenotype associated with PKCz loss.221 Loss of PKCz
also allows glucose-addicted human cancer cells to reprogram
their metabolism in response to glucose deprivation by
augmenting the utilization of glutamine through the serine
biosynthetic pathway.222
Accumulating evidence established that PKCi is an oncogenic
kinase and that it contributes to the transformed phenotype.
Overexpression of PKCi is observed in many human cancers,
Figure 6. Roles of atypical PKCs in cancer. Most evidence points to
PKCz as a tumor suppressor protein and PKCi as an oncogenic
kinase.
Figure 5. Phenotype of prostate-specific PKCe transgenic mice. Prostate-specific overexpression of PKCe in mice under the control of the
probasin (PB) promoter leads to a preneoplastic phenotype. Representative photomicrographs for hematoxylin and eosin (H&E), phospho-Akt,
phospho-NF-kB and phospho-Stat3 staining in ventral prostates from 12-month-old male PB-PKCe mice are shown.
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including colon, lung, pancreas, breast, prostate and ovarian
cancer. The PKCi gene (PRKCI) is amplified in some human
cancers,223–225 although PKCi overexpression is not always
associated with gene amplification.226–228 This has been well
summarized in a review by Murray et al.229
PKCi expression is elevated in NSCLC tumors and cell lines, and
is required for the transformed phenotype of NSCLC cells
harboring oncogenic K-Ras mutation.230–233 NSCLC cell lines
without Ras mutation also depend on PKCi for their malignant
phenotype if they harbor PRKCI gene amplification.233 PKCi
mediates its effects through a Rac1-Pak-Mek-Erk-dependent
mechanism.88 By means of a proteomics approach, Justilien
et al.234 identified the Rho-GEF Ect2 as a component of the PKCi–
Par6 complex that is required for transformed growth. The Ect2
gene co-amplifies with PRKCI suggesting a coordinated
mechanism for tumorigenesis. Disruption of the PKCi–Par6
interaction, as caused with the anti-rheumatic agent
aurothiomalate, potently inhibits growth of PKCi-overexpressing
cell lines. Anti-rheumatic agent aurothiomalate inhibits K-Ras-
mediated expansion of bronchoalveolar stem cells and lung tumor
growth in vivo.231,235 On the other hand, aPKCs appear to be
dispensable for mammalian hematopoietic stem cell function.236
PKCi has been also implicated in colon and pancreatic cancer
using cell lines and animal models.227,228 PKCi is required for
hedgehog signaling in basal cell carcinomas. Indeed, PKCi
functions downstream of smoothened (SMO) to phosphorylate
and activate the GLI1 transcription factor. Moreover, PKCi is
upregulated in tumors resistant to SMO inhibitors, and targeting
PKCi suppresses the growth of resistant basal carcinoma cell
lines.237 Other interesting signaling connections have been
established for PKCi, including mutually antagonistic regulation
with RhoB in glioblastoma cell invasion,238 links with the NF-kB
pathway239,240 as well as association with cell cycle proteins cyclin
E in ovarian cancer,224 and S-phase kinase-associated protein 2 in
esophageal cancer.241
FINAL REMARKS
Tangible progress has been made in the last 30 years in
understanding the regulation and cellular functions of PKC
isozymes in cancer. The picture that emerged, however, is less
than clear. What we have learned over the last years is that the
biology of PKC isozymes is exceptionally complex, and that many
studies in cell lines do not necessarily apply to in vivo models. For
the next wave of studies on PKC function, the generation of
animal models recapitulating the scenarios observed in different
cancer types should be a priority. However, it is still not known
whether the activation status of different members of the PKC
family is altered in cancer and whether activated PKCs functionally
interact with oncogenes and tumor suppressors genes driving the
tumorigenic and metastatic phenotype.
One would expect that PKC is a promising target for cancer
therapy, but only for specific PKC isozymes that display oncogenic
activity, such as PKCe and PKCi. The portfolio of available PKC
inhibitors remains narrow, and unfortunately the majority of
compounds lack specificity among members of the PKC family or
even with other kinases unrelated to PKC. Hence, there is a great
need to design selective small-molecule inhibitors for PKC
isozymes that have sufficient potency to impair PKC function
in vivo. There may be concrete opportunities to rationally design
inhibitors against the ATP-binding site, but this is still challenging
due to the high homology among PKCs in that region. Some
examples of small molecules capable of disrupting protein–
protein interactions for PKC isozymes provided proof-of-principle
for alternative approaches in the design of PKC modula-
tors.175,235,242 C1 domain ligands, such as the bryostatins,243,244 did
not showmajor beneficial effects in patients despite their anti-tumor
effects in mice.242 One may envision that PKC isozyme-specific
inhibitors may possibly work in combined therapies with
chemotherapeutic agents for discrete cancer types. Translating
PKC modulators into a clinical setting remains a formidable
challenge that we face for the next years.
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